Medical Device Contracting
Drug Delivery Platform
Advanced Biomanufacturing Technologies
Research and Development
Custom Fiber Extrusion Technology
View presentations about the latest medical advancement focuses of Secant Group
Breaking the Norm: Showcasing Hydralese™as a Superior Polymer in Long-acting Drug Delivery
In this presentation from American Chemical Society Spring 2022, Jarrod Cohen, PhD, Scientist II, provides evidence as to why Secant Group's polymer platform Hydralese™ (PGSU) is a strong new excipient candidate for drug delivery applications. Evidence is based on the platform’s scalable and reproducible polymer synthesis, minimal to no burst release for active pharmaceutical ingredients (APIs), diverse set of API-polymer forms, and established processes for scale-up and characterization of combination products.
Next-Generation Long-Acting Dosage Forms Using Hydralese™ (PGSU) Surface-Eroding Elastomers
Secant Group's Hydralese™ (PGSU) technology for controlled release consists of biodegradable and shelf-stable polymers that can be manufactured into implants, microspheres, coatings, and gastroretentive devices. Stephanie Reed, PhD, Director of Translational Product Development, discusses how long-acting Hydralese formulations sustain zero-order release kinetics lasting many months to years at very high drug payloads while offering mechanical flexibility and excellent biocompatibility suitable for a variety of anatomical sites and therapies.
Launching a New Polymer for Controlled Release: Challenges, De-risking, and Breaking Through Historical Precedent
Stephanie Reed, PhD, Director of Translational Product Development, discusses overcoming the challenges of commercializing novel polymer technologies for controlled release. In this presentation from Controlled Release Society 2021, Dr. Reed addresses the current state of controlled release polymers on the market, datasets needed to de-risk a new excipient for use by pharmaceutical formulators, and how to bring better next-generation drug delivery solutions to patients. (Presentation begins at 4:41)
Development of Long-acting Implantable Drug Delivery Systems Using Hydralese™
Stephanie Reed, PhD, Director of Translational Product Development, discusses Secant Group's Hydralese™ technology platform as a new alternative for controlled active delivery at BIOMEDevice Digital Express 2020. Dr. Reed discusses the benefits of Hydralese™, a highly flexible, water impermeable, shelf-life stable, and biocompatible elastomer that biodegrades via surface erosion and maintains a near-constant release rate across drug loadings.
Medical Device Textiles
From Sketch to Scale: Building a Valuable Medical Device Textile Partnership
In this interview, originally broadcast during BIOMEDevice 2021, Secant Group’s Director of Innovation & Product Strategy, Andrew Metzger, discusses how OEMs can be prepared to advance projects into commercialization by collaborating with a highly responsive partner. The ideal medical device component partner provides rapid customer response, in-house services from prototyping to finishing, an unwavering commitment to quality, and the experience to navigate supply chain challenges.
Advanced Textile Solutions for Structural Heart Devices
Choosing the right medical textiles for cardiovascular devices used in structural heart procedures such as transcatheter heart valve replacement or repair of left atrial appendage occlusion requires careful consideration. Learn how the experts apply advanced medical textile-forming technologies to create effective fabrics used in cardiovascular devices to meet critical needs to enhance patient recovery and quality of life.
Overcoming Design Challenges with Novel Resorbable Biomaterials
Director of Research Jeremy Harris, PhD, offers guidance for overcoming key design challenges with resorbable biomaterials on the journey to commercialization. Challenges include navigating the biomaterials market, identifying the ideal properties of a biomaterial, addressing compliance mismatch, protecting intellectual property, and knowing when to start working with the FDA.
What is braiding?
Braiding for medical textiles is a process of taking several strands of yarn or wire and interlacing them over one another to form a diagonally overlapping pattern.
What is knitting?
Knitting for medical textiles is a technology in which a flat, broad, or tubular fabric is formed by a series of interconnecting loops.
What is weaving?
Weaving for medical textiles is creating a fabric by placing warp threads vertically with the length of the fabric and inserting a filling yarn, or a weft thread, horizontally along the width to create the fabric.